Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
Go back to Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline| Amarin Corp Plc (NASDAQ: AMRN) | Delayed: 16.41 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.41 | 52 Week High | $3.65 | |||
| Open | $16.41 | 52 Week Low | $1.24 | |||
| Day High | $16.41 | P/E | N/A | |||
| Day Low | $16.41 | EPS | $0.00 | |||
| Volume | 2 | |||||
